https://blueblood.com.tw/wp-content/uploads/2024/09/3d-render-medical-background-with-dna-strands-connecting-dots-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302011-11-01 12:00:292025-10-09 12:05:16Held a clinical trial consultation meeting with the U.S. FDA regarding NEGF, a drug candidate for promoting diabetic wound healing
https://blueblood.com.tw/wp-content/uploads/2025/03/carbon-nanotubes-nanotechnology-3d-rendering-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302011-11-01 12:00:112025-08-28 10:15:15BBACN composition for antibacterial and anti-inflammatory applications received Singapore patent approval.
https://blueblood.com.tw/wp-content/uploads/2024/09/dna-genetic-biotechnology-science-with-scientist-rsquo-s-hands-disruptive-technology-remix.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302011-09-01 12:00:322025-10-09 11:24:52Held consultation meeting with the US FDA for the NEGF drug promoting wound healing for diabetic patients.
Held a clinical trial consultation meeting with the U.S. FDA regarding NEGF, a drug candidate for promoting diabetic wound healing
BBACN composition for antibacterial and anti-inflammatory applications received Singapore patent approval.
Held consultation meeting with the US FDA for the NEGF drug promoting wound healing for diabetic patients.